Market Research Logo

H1N1 Infection - Pipeline Review, H1 2016

H1N1 Infection - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘H1N1 Infection - Pipeline Review, H1 2016’, provides an overview of the H1N1 Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for H1N1 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H1N1 Infection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of H1N1 Infection
  • The report reviews pipeline therapeutics for H1N1 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved H1N1 Infection therapeutics and enlists all their major and minor projects
  • The report assesses H1N1 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for H1N1 Infection
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for H1N1 Infection
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
H1N1 Infection Overview
Therapeutics Development
Pipeline Products for H1N1 Infection – Overview
Pipeline Products for H1N1 Infection – Comparative Analysis
H1N1 Infection – Therapeutics under Development by Companies
H1N1 Infection – Therapeutics under Investigation by Universities/Institutes
H1N1 Infection – Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
H1N1 Infection – Products under Development by Companies
H1N1 Infection – Products under Investigation by Universities/Institutes
H1N1 Infection – Companies Involved in Therapeutics Development
Adamas Pharmaceuticals, Inc.
Akshaya Bio Inc.
Altimmune, Inc.
Antigen Express, Inc.
Beijing Minhai Biotechnology Co., Ltd
CEL-SCI Corporation
Cilian AG
CSL Limited
EpiVax, Inc.
Etubics Corporation
Gemmus Pharma Inc.
iBio, Inc.
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kineta, Inc.
Kyowa Hakko Kirin Co., Ltd.
Medicago Inc.
MedImmune, LLC
Microbiotix, Inc.
Mucosis B.V.
NanoViricides, Inc.
NewLink Genetics Corporation
Novavax, Inc.
OPKO Health, Inc.
PeptiDream Inc.
Sarepta Therapeutics, Inc.
Sirnaomics, Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
Theraclone Sciences, Inc.
Touchlight Genetics Limited
United Therapeutics Corporation
Vaxart, Inc.
Vironova AB
Visterra, Inc.
Zydus Cadila Healthcare Limited
H1N1 Infection – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-06 - Drug Profile
ADS-324 - Drug Profile
AEA-35p - Drug Profile
Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza - Drug Profile
Aspidasept - Drug Profile
C-05 - Drug Profile
CiFlu - Drug Profile
CR-9114 - Drug Profile
diridavumab - Drug Profile
Fludase - Drug Profile
FluGEM - Drug Profile
FVH-1 - Drug Profile
Gamma-Flu - Drug Profile
GP-1001 - Drug Profile
GP-1681 - Drug Profile
GREFLU/CAL - Drug Profile
H1N1 [A/Aichi/2/68] vaccine - Drug Profile
HB-36.6 - Drug Profile
Human Antibody Based Vaccines - Drug Profile
iHA-24 - Drug Profile
infectious vaccine - Drug Profile
Influ-nRNA - Drug Profile
influenza [serotype A] vaccine - Drug Profile
influenza [strain A/H1N1] vaccine - Drug Profile
influenza [strain A/H1N1] vaccine - Drug Profile
influenza [strain A/H1N1] vaccine - Drug Profile
influenza [strain H1N1] (monovalent) vaccine - Drug Profile
influenza [strain H1N1] (mutivalent) vaccine - Drug Profile
influenza [strain H1N1] vaccine - Drug Profile
influenza [strain H1N1] vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile
influenza vaccine - Drug Profile
influenza vaccine - Drug Profile
INO-3510 - Drug Profile
JNJ-872 - Drug Profile
LEAPS-H1N1-DC - Drug Profile
MBX-2329 - Drug Profile
MBX-2546 - Drug Profile
NEO-8877 - Drug Profile
NVINF-1 - Drug Profile
NVINF-2 - Drug Profile
pertussis [strain BPZE1] vaccine - Drug Profile
PNSIA-28 - Drug Profile
PNSIA-49 - Drug Profile
radavirsen - Drug Profile
Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile
RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection - Drug Profile
Small Molecules for RSV and Influenza A Infections - Drug Profile
Small Molecules to Agonize IRF-3 for Viral Infections - Drug Profile
Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile
Small Molecules to Inhibit Influenza A Endonuclease for H1N1 Infections - Drug Profile
STP-702 - Drug Profile
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
TCN-032 - Drug Profile
TVX-002 - Drug Profile
VH-244 - Drug Profile
VIS-410 - Drug Profile
VNFC-045 - Drug Profile
VNFC-051 - Drug Profile
VXAA-1.1 - Drug Profile
Z-3G1 - Drug Profile
H1N1 Infection – Recent Pipeline Updates
H1N1 Infection - Dormant Projects
H1N1 Infection – Discontinued Products
H1N1 Infection – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for H1N1 Infection, H1 2016
Number of Products under Development for H1N1 Infection – Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2016
H1N1 Infection – Pipeline by Adamas Pharmaceuticals, Inc., H1 2016
H1N1 Infection – Pipeline by Akshaya Bio Inc., H1 2016
H1N1 Infection – Pipeline by Altimmune, Inc., H1 2016
H1N1 Infection – Pipeline by Antigen Express, Inc., H1 2016
H1N1 Infection – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
H1N1 Infection – Pipeline by CEL-SCI Corporation, H1 2016
H1N1 Infection – Pipeline by Cilian AG, H1 2016
H1N1 Infection – Pipeline by CSL Limited, H1 2016
H1N1 Infection – Pipeline by EpiVax, Inc., H1 2016
H1N1 Infection – Pipeline by Etubics Corporation, H1 2016
H1N1 Infection – Pipeline by Gemmus Pharma Inc., H1 2016
H1N1 Infection – Pipeline by iBio, Inc., H1 2016
H1N1 Infection – Pipeline by ILiAD Biotechnologies, LLC, H1 2016
H1N1 Infection – Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
H1N1 Infection – Pipeline by Johnson & Johnson, H1 2016
H1N1 Infection – Pipeline by Kineta, Inc., H1 2016
H1N1 Infection – Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
H1N1 Infection – Pipeline by Medicago Inc., H1 2016
H1N1 Infection – Pipeline by MedImmune, LLC, H1 2016
H1N1 Infection – Pipeline by Microbiotix, Inc., H1 2016
H1N1 Infection – Pipeline by Mucosis B.V., H1 2016
H1N1 Infection – Pipeline by NanoViricides, Inc., H1 2016
H1N1 Infection – Pipeline by NewLink Genetics Corporation, H1 2016
H1N1 Infection – Pipeline by Novavax, Inc., H1 2016
H1N1 Infection – Pipeline by OPKO Health, Inc., H1 2016
H1N1 Infection – Pipeline by PeptiDream Inc., H1 2016
H1N1 Infection – Pipeline by Sarepta Therapeutics, Inc., H1 2016
H1N1 Infection – Pipeline by Sirnaomics, Inc., H1 2016
H1N1 Infection – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
H1N1 Infection – Pipeline by TechnoVax, Inc., H1 2016
H1N1 Infection – Pipeline by Theraclone Sciences, Inc., H1 2016
H1N1 Infection – Pipeline by Touchlight Genetics Limited, H1 2016
H1N1 Infection – Pipeline by United Therapeutics Corporation, H1 2016
H1N1 Infection – Pipeline by Vaxart, Inc., H1 2016
H1N1 Infection – Pipeline by Vironova AB, H1 2016
H1N1 Infection – Pipeline by Visterra, Inc., H1 2016
H1N1 Infection – Pipeline by Zydus Cadila Healthcare Limited, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
H1N1 Infection Therapeutics – Recent Pipeline Updates, H1 2016
H1N1 Infection – Dormant Projects, H1 2016
H1N1 Infection – Dormant Projects (Contd..1), H1 2016
H1N1 Infection – Dormant Projects (Contd..2), H1 2016
H1N1 Infection – Dormant Projects (Contd..3), H1 2016
H1N1 Infection – Discontinued Products, H1 2016
List of Figures
Number of Products under Development for H1N1 Infection, H1 2016
Number of Products under Development for H1N1 Infection – Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report